



Purpose: the aim of the present study was to evaluate
the clinical outcome of the treatment  of osteochon-
dritis dissecans (OCD) of the knee with a type-I colla-
gen-hydroxyapatite nanostructural biomimetic osteo-
chondral scaffold.
Methods: twenty-three patients affected by sympto-
matic knee OCD of the femoral condyles, grade 3 or
4 of the International Cartilage Repair Society (ICRS)
scale, underwent biomimetic scaffold implantation.
The site of the defect was the medial femoral condyle
in 14 patients, whereas in 9 patients the lateral femoral
condyle was involved. The average size of the defects
was 3.5±1.43 cm2. All patients were clinically evaluat-
ed using the ICRS subjective score, the IKDC objec-
tive score, the EQ-VAS and the Tegner Activity Score.
Minimum follow-up was two years. MRI was per-
formed at 12 and 24 months after surgery and then
every 12 months thereafter.
Results: the ICRS subjective score improved from the
baseline value of 50.93±20.6 to 76.44±18.03 at the 12
months (p<0.0005) and 82.23± 17.36 at the two-year
follow-up (p<0.0005). The IKDC objective score con-
firmed the results.The EQ-VAS showed a significant
improvement from 3.15±1.09 to 8.15±1.04 (p<0.0005)
at two years of follow-up. The Tegner Activity Score
improvement was statistically significant (p<0.0005).
Conclusions: biomimetic scaffold implantation was a
good procedure for treating grade 3 and 4 OCD, in
which other classic techniques are burdened by differ-
ent limitations. This open one-step surgery gave
promising stable results at short-term follow-up. 
Level of evidence: Level IV, therapeutic case series.
Key words: cartilage, knee, osteochondral lesions,
ostechondritis dissecans, scaffold.
Introduction
Chondral and osteochondral lesions are relatively
common and are often caused by traumatic injury (1).
In the past 20 years, there have been many studies
dealing with cartilage restoration and, even though the
quality of restored cartilage is now debated, a series of
satisfying results have been reported in the literature
(2-13). The treatment becomes increasingly challeng-
ing in the presence of larger defects and when there is
involvement of the subchondral bone (8,14-18).
Osteochondritis dissecans (OCD) is an acquired le -
sion of the subchondral bone that may result in sepa-
ration and instability of the overlying articular carti-
lage (19,20). Among the multiple causes hypothe-
sized, repetitive microtrauma correlated with a possi-
ble vascular insufficiency is the most credited theory
(19). Whereas juvenile patients with small or stable
lesions have a much better prognosis and the potential
for healing by non-operative management, unstable
lesions or OCD in skeletally mature individuals often
do not respond to non-operative measures and require
surgical intervention (19).
In large lesions of this kind, the use of autologous
osteochondral transplantation and mosaic plasty is
limited by donor site availability (21). Autologous
chondrocyte implantation (ACI), on the other hand, is
not limited by the size of the lesion and has been used
successfully in the treatment of osteochondral lesions,
adding the autogenous bone implant before the
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implantation of autologous chondrocytes (14,15, 22-
24). However, the technique involves two surgical pro-
cedures, performed several months apart, which
implies long functional recovery times. Efforts to over-
come these limitations have led to increasing use, with
excellent results, of fresh allograft transplantation (25,
26). However, the management of this procedure is
not straight forward and sometimes impossible, due to
high costs, lack of donors and, in particular, the need
to implant the allograft within 14 days.
To overcome these limitations, a cellular biphasic or
triphasic scaffolds have recently been developed with the
aim of promoting and inducing both subchondral bone
and cartilage regeneration (16, 17, 27-32). Currently,
only a few scaffolds have obtained the European
Conformity (CE) certification and are available for clin-
ical application in Europe (16, 17, 28, 29, 33, 34).
The aim of the present study was to evaluate the clin-
ical outcome of the treatment of OCD of the knee
with a type-I collagen-hydroxyapatite nanostructural
biomimetic osteochondral scaffold. 
Methods
Twenty-three consecutive patients affected by sympto-
matic knee OCD of the femoral condyles, grade 3 or
4 of the International Cartilage Repair Society (ICRS)
scale, underwent implantation of a biomimetic oste-
chondral scaffold (MaioRegen; Fin-Ceramica Faenza
SpA, Faenza, Italy) between 2009 and 2011 at three
different centers highly specialized in the treatment of
knee cartilage disorders.
MaioRegen is a three-dimensional matrix that mimics
osteocartilaginous tissue. The scaffold consists of
hydroxyapatite nanocrystals nucleated on type 1 colla-
gen fibers present, in different concentrations, in three
layers: the first layer consists entirely of type I collagen
and has a smooth surface; the intermediate layer,
which is thicker, is a combination of type I collagen
(60%) and hydroxyapatite (40%); the third layer,
which is thinner, consists of a mineralized blend of
type I collagen (30%) and hydroxyapatite (70%) and
it mimics the subchondral bone (Fig. 1).
All the patients gave their informed consent prior to
their inclusion in the study, which had ethics commit-
tee approval and was performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki and its subsequent amendments. Exclusion
criteria were: non-corrected axial malalignment (con-
sidered as above 5° from the normal axis), evaluated
clinically and via radiographic examination, and the
presence of co-morbidities such as: infectious, neo-
plastic, metabolic, and systemic inflammatory disor-
ders. 
The patients included 19 men and 4 women, with a
mean age of 25.5±7.7 years. The site of the defects was
the medial femoral condyle in 14 patients, whereas in
9 patients the lateral femoral condyle was involved.
The average size of the defects was 3.5±1.43 cm2.
Surgical procedure
The surgery was performed under spinal or limb anes-
thesia. A tourniquet was positioned on the thigh with
the patient in a supine position. After an arthroscopic
evaluation of the knee, the lesion was exposed through
a lateral or medial parapatellar approach and was pre-
pared with a drill specific for this purpose. The scle-
rotic subchondral bone was eliminated and an area
approximately 9 mm in depth with a stable base was
created to house the scaffold, which was then implant-
ed press fit into the area (Fig. 2). The stability of the
transplant was tested by cyclic flexion-extension of the
knee while the graft was visualized, both before and
after tourniquet removal. On the second postoperative
day, mobilization of the knee was started. Early iso-
metric and isotonic exercises and controlled mechani-
cal compression were performed. Muscular voluntary
contraction and neuromuscular electrical stimulation
were prescribed and could be started at patient dis-
Fig. 1. MaioRegen scaffold.
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charge. In the third or fourth week, weight touchdown
with crutches was allowed, and the patient could then
move progressively toward full weight-bearing, which
was achieved within six to eight weeks of the surgery.
Outcome measurement
The clinical outcome in all the patients was assessed
using the ICRS subjective score and the International
Knee Documentation Committee (IKDC) score at 12
and at 24 months after the operation, and every 12
months thereafter.
Improvement in quality of life was measured using the
EQ-VAS score and resumption of sporting activity
using the Tegner Activity Score. The patients under-
went magnetic resonance imaging (MRI) preopera-
tively, at 12 and at 24 months after the operation, and
every 12 months thereafter.
Statistical analysis
All the statistical analyses were carried out using the
SPSS (Statistical Package of Social Sciences, Chicago,
IL, USA) for Windows software program version 13.0.
A p value of less than 0.05 was considered statistically
significant. The results were expressed as mean values
± SD. The Kolmogorov-Smirnov test was performed
to assess the normal data distribution. The paired T
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Fig. 2. Surgical technique of MaioRegen implantation. A:Arthroscopic
appearance of an osteochondritis dissecans of the medial femoral
condyle. B:The lesion is exposed through a medial parapatellar inci-
sion. C:Resected osteochondral fragment. D:MaioRegen scaffold
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test for normally distributed data, or the Wilcoxon test
for non-normally distributed data, were used to test
for significant differences between the baseline and
various follow-up measurements.
Results
No patients were lost at follow-up. Statistically signif-
icant increases were recorded in all the assessment
scores at the 12-month and 24-month follow-ups. In
two cases the treatment failed, one on the lateral
femoral condyle and one on the medial femoral
condyle, with these patients continuing to experience
pain and functional limitation of the joint.
Improvements were recorded in the ICRS subjective
score, which increased from the baseline value of
50.93±20.6 to 76.44±18.03 at the 12-month follow-
up (p<0.0005) and 82.23±17.36 at the 2-year follow-
up.
Before surgery, more than 50% of the patients per-
ceived abnormal or very abnormal knee sensations
(IKDC objective C and D grade), due to moderate or
severe swelling of the knee.
Assessment of the patients at the first follow-up (one
year after surgery) revealed an improvement, and at
two years the following scores were recorded: A, 11
patients; B, 7 patients; C, 2 patients, D, only 1
patient.
The EQ-VAS score also showed a significant increase,
from 3.15±1.09 to 8.15±1.04 (p<0.0005) at the 2-
year follow-up, with satisfaction recorded in 85% of
the patients.
The Tegner Activity Score showed a significant
increase (from 2.34±0.64 to 5.60±1.72 at the two-year
follow-up), even though it did not reach the pre-injury
level (6.04±1.89). 
High-resolution MRI scans were performed in all the
patients and showed complete filling of the defect in
80% of the lesions; in 70% of cases the repair tissue
was isointense in relation to the adjacent cartilage. In
all cases, the scaffold was still detectable at the level of
the subchondral bone at the two-year follow, produc-
ing a different signal with respect to the adjacent sub-
chondral bone. 
Nevertheless, no case showed signs of subchondral
bone impairment (such as subchondral edema)
(Fig. 3).
Discussion
The present study suggests that MaioRegen collagen-
hydroxyapatite osteochondral scaffold can be used to
treat knee OCD with good clinical results at 2-year
follow-up.
Osteochondral lesions are particularly difficult to treat
as they involve two types of tissue that show different
biomechanical features and healing capacity (19, 20).
One of the approaches proposed for the treatment for
deep osteochondral defects of the knee is staged open
or arthroscopic bone grafting followed by ACI 4-9
months later (10, 11). The clinical outcome of such a
procedure has not yet been reported; however, the
need for three surgical procedures after the diagnosis
poses a significant burden to the patient.
Minas and Peterson (24) and Peterson et al. (35, 36)
have advocated the ACI ‘‘sandwich technique’’ as an
alternative. Unfortunately, the outcome has been
reported in only 7 patients. With the advent of the so-
called “second-generation” ACI to overcome the limi-
tations and the problems related to the “first-genera-
tion” ACI, a two-step procedure was proposed by dif-
ferent authors for the treatment for osteochondral
lesions (22, 23). Bartlett et al. (2), Ochs et al. (12) and
recently Filardo et al. (7) analyzed the clinical outcome
in patients affected by OCD with the use of second-
generation ACI associated with bone grafting harvest-
ed from different site (iliac crest, tibial cancellous
bone), obtaining satisfactory results.
Despite the good results reported in the literature,
these techniques present a number of problems: first
of all, the bone grafting site (proximal tibia, iliac crest)
is a source of post-operative pain and morbidity, which
are directly proportional to the surgical exposure; in
addition, the need for two surgical steps makes for
longer recovery times.
In the United States, a different treatment option has
been developed; fresh osteochondral allografting has
been used to treat large osteochondral lesions of the
knee (post-traumatic, vascular or idiopathic) and given
excellent results in cases of OCD of the femoral
condyle (25,26). However, this technique is burdened
by high costs and difficult management due to the
need to implant the graft within 14 days. For these
reasons, many authors have turned their attention to
the use of biphasic biomaterials with the capacity to
promote joint surface regeneration by exploiting the
differentiation (induced by the properties of the scaf-
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fold itself ) of bone marrow stem cells (31, 32). Various
experimental studies, both in vitro and in vivo, have
been published (27,30), but in our experience only
two scaffolds are available in clinical practice for the
treatment of osteochondral lesions. The first is a
biopolymercomposite of poly (D,L-lactide-co-glycol-
ide), polyglycolic acid and calcium sulfate (TruFit;
Smith&Nephew, Andover, Ma). The results obtained
following implantation of this osteochondral substi-
tute are discordant (33,34).
The second is MaioRegen. This has given promising
results in animals and patients (16-18, 20, 28, 29).
Fig. 3. Postoperative imaging of MaioRegen implantation. A-B: MRI follow-up at one year. It is possible to note the
scaffold in situ and the ongoing differentiation process. C-D: MRI follow-up at two years. The scaffold is still rec-







Our study confirmed these results. The ICRS subjec-
tive score was found to be significantly increased, both
at the 12-month and the 24-month follow-up. The
Tegner Activity Score increased significantly and
almost reached the pre-injury level. We had 13
patients who were athletes before symptom onset and
11 of them returned to the previous level of sports
activity between one and two years after the operation.
In conclusion, the MaioRegen biomimetic scaffold is
an off-the-shelf, cell-free and cost-effective implant
that can regenerate cartilage and osteochondral
defects. Its implantation is a one-step procedure that
can be used for difficult pathologies such as ostechon-
dral lesions and OCD, in which other regenerative
treatments have proved to be burdened by several lim-
itations. However, the results are certainly to be con-
firmed at longer term follow-up.
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